DK158883A - Inklusionsforbindelser ud fra lankacidin og cyclodextrin samt anvendelse deraf - Google Patents

Inklusionsforbindelser ud fra lankacidin og cyclodextrin samt anvendelse deraf Download PDF

Info

Publication number
DK158883A
DK158883A DK158883A DK158883A DK158883A DK 158883 A DK158883 A DK 158883A DK 158883 A DK158883 A DK 158883A DK 158883 A DK158883 A DK 158883A DK 158883 A DK158883 A DK 158883A
Authority
DK
Denmark
Prior art keywords
linkacidin
cyclodextrin inclusion
inclusion compounds
compounds
cyclodextrin
Prior art date
Application number
DK158883A
Other languages
Danish (da)
English (en)
Other versions
DK158883D0 (da
Inventor
Setsuo Harada
Junya Okada
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of DK158883D0 publication Critical patent/DK158883D0/da
Publication of DK158883A publication Critical patent/DK158883A/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK158883A 1982-04-12 1983-04-11 Inklusionsforbindelser ud fra lankacidin og cyclodextrin samt anvendelse deraf DK158883A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57061343A JPS58177949A (ja) 1982-04-12 1982-04-12 ランカシジン群抗生物質包接化合物

Publications (2)

Publication Number Publication Date
DK158883D0 DK158883D0 (da) 1983-04-11
DK158883A true DK158883A (da) 1983-10-13

Family

ID=13168385

Family Applications (1)

Application Number Title Priority Date Filing Date
DK158883A DK158883A (da) 1982-04-12 1983-04-11 Inklusionsforbindelser ud fra lankacidin og cyclodextrin samt anvendelse deraf

Country Status (8)

Country Link
US (1) US4497803A (es)
EP (1) EP0091782B1 (es)
JP (1) JPS58177949A (es)
CA (1) CA1216581A (es)
DE (1) DE3372577D1 (es)
DK (1) DK158883A (es)
ES (1) ES8405032A1 (es)
ZA (1) ZA832471B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
HU196230B (en) * 1983-12-29 1988-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing water-soluble forms of polyene antibiotics and pharmaceutics comprising such active ingredient and plant protective with antifungal effect
US4616008A (en) * 1984-05-02 1986-10-07 Takeda Chemical Industries, Ltd. Antibacterial solid composition for oral administration
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
JPS61207380A (ja) * 1985-03-11 1986-09-13 Taiyo Yakuhin Kogyo Kk モベンゾキサミンの経口製剤
US4914206A (en) * 1985-10-06 1990-04-03 Takeda Chemical Industries, Ltd. Lankacidin derivatives and production thereof
ES2058057T3 (es) * 1985-12-05 1994-11-01 Takeda Chemical Industries Ltd Derivados de lancacidina y su produccion.
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AT400674B (de) * 1991-07-24 1996-02-26 Biochemie Gmbh Pharmazeutische pleuromutilin-zubereitung
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
DE69720283T2 (de) * 1996-12-30 2004-01-29 Univ Johns Hopkins Med Bestimmung der krebsanfälligkeit eines organs oder gewebes durch bestimmung seiner zellprägung
EP1332756A3 (en) * 1996-12-30 2003-12-10 The Johns Hopkins University School Of Medicine Compositions and methods for restoring a normal pattern of imprinting to cells
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
MEP34508A (en) * 2003-03-28 2011-02-10 Ares Trading Sa Cladribine formulations for improved oral and transmucosal delivery
ME00249B (me) * 2003-03-28 2011-05-10 Ivax Corp Oralne formulacije kladribina
EP2272503B1 (en) 2003-03-28 2013-03-20 Ares Trading S.A. Oral formulations of cladribine
AU2005207786B2 (en) 2004-01-29 2010-11-25 Eisai R & D Management Co., Ltd Method of stabilizing macrolide compound
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959580A (en) * 1956-10-17 1960-11-08 Univ Minnesota Formation of inclusion compounds
JPS4810442B1 (es) * 1968-10-26 1973-04-03
US3869443A (en) * 1971-02-25 1975-03-04 Sterling Drug Inc N,N{40 -Heptamethylenebis(4-trifluoromethoxybenzamide)-{62 -cyclodextrin inclusion complex
JPS5738569B2 (es) * 1974-03-27 1982-08-16
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
JPS5724312A (en) * 1980-07-18 1982-02-08 Taisho Pharmaceut Co Ltd Polyether antibiotic clathrate compound
US4407795A (en) * 1981-07-16 1983-10-04 American Cyanamid Company Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use

Also Published As

Publication number Publication date
US4497803A (en) 1985-02-05
JPH0336827B2 (es) 1991-06-03
ES521362A0 (es) 1984-05-16
CA1216581A (en) 1987-01-13
DK158883D0 (da) 1983-04-11
DE3372577D1 (en) 1987-08-27
EP0091782A2 (en) 1983-10-19
EP0091782B1 (en) 1987-07-22
ZA832471B (en) 1983-12-28
EP0091782A3 (en) 1984-09-26
ES8405032A1 (es) 1984-05-16
JPS58177949A (ja) 1983-10-18

Similar Documents

Publication Publication Date Title
DK158883D0 (da) Inklusionsforbindelser ud fra lankacidin og cyclodextrin samt anvendelse deraf
NO831494L (no) Laaseanordning
TR20971A (tr) 1-benzoil-3-(izoksazolil veya benzizoksazolil)-uereler
BR8005278A (pt) Hidrociclone
ES258891Y (es) Bolsa
BR8100907A (pt) Pneumatico
FI822073A0 (fi) Sil
FI811866L (fi) Stomme till en faellbar gasfjaedermanoevrerad vilstol
NO831493L (no) Laaseanordning
BR8103444A (pt) Hidrociclone
DK572581A (da) Cephalosporinderivater
SE8103306L (sv) Skrivleksak
DK65581A (da) Transporterende bageovn
JPS55119240A (en) Buffer string
KR830000681U (ko) 샤아프 펜슬
IT1136877B (it) Ammortizzatore
AT359439B (de) Hydrozyklon
DK196683D0 (da) Substitueret urinstof og herbicid indeholdende dette
ES258237Y (es) Tampon periodico
BR8101623A (pt) Pneumatico
ATA659479A (de) Strassenleitpfahl
BR8101624A (pt) Pneumatico
KR830000678U (ko) 샤아프 펜슬
IT1133496B (it) Motocarriola monocingolo
BR6000868U (pt) Balao

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment
PBP Patent lapsed